Views & Analysis A collaborative approach to greater diversity in clinical tr... The need for diversity in clinical trial populations has been a topic of discussion across regulators and the industry in general for decades.
Digital Company profile: Evidera Data disruption and applying ‘enabled intelligence’ to convert the promise shown in clinical trials into real-world success.
R&D Opening doors in pharmaceutical development Evidera surveys the adoption of machine learning by the pharmaceutical industry and looks at how it can increase R&D efficiencies.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.